Paraoxonase-1 (PON1) status in pancreatic cancer: Relation to clinical parameters

Folia Biologica (Czech Republic)

Volumn 58, Issue 6, 2012, Pages 231-237

  Vecka, Marek ^a   Jachymova M ^a   Vavrova L ^a   Kodydkova J ^a   Macasek J ^a   Urbanek M ^a   Krechler, T ^a   Slaby A ^a   Duskova J ^a   Muravska A ^a   Zak A ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Malnutrition; Pancreatic cancer; Paraoxonase 1 (PON1) polymorphisms; PON1 arylesterase lactonase activities

Indexed keywords

ALBUMIN; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; GLUCONOLACTONASE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC CORRELATION; GENOTYPE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; OXIDATIVE STRESS; PANCREAS CANCER; PROTEIN METABOLISM;

EID: 84879801386     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ahotupa, M., Ruutu, M., Mäntylä, E. (1996) Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin. Biochem. 29, 139-144. (Pubitemid 26115431)
2. Akcay, M. N., Polat, M. F., Yilmaz, I., Akcay, G. (2003) Serum paraoxonase levels in pancreatic cancer. Hepato-Gastroenterology 50, Suppl II, ccxxv-ccxxvii.
3. Alberti, K. G., Zimmet, P. Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet. Med. 15, 539-553. (Pubitemid 28319935)
4. Arioz, D. T., Camuzcuoglu, H., Toy, H., Kurt, S., Celik, H., Erel, O. (2009) Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer. Eur. J. Gynaecol. Oncol. 30, 679-682.
5. Bhattacharyya, T., Nicholls, S. J., Topol, E. J., Zhang, R., Yang, X., Schmidt, D., Fu, X., Shao, M., Brennan, D. M., Ellis, S. G., Brennan, M. L., Allayee, H., Lusis, A. J., Hazen, S. L. (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299, 1265-1276. (Pubitemid 351439073)
6. Deakin, S., Leviev, I., Nicaud, V., Gustini, P., Grison, E., Pizzolo, F., Friso, S., Trabetti, E., Pignatti, P.F., Corrocher, R., Olivieri, O., Girelli, D. (2002) Paraoxonase-1 L55M polymorphism is associated with abnormal oral glucose tolerance test and differentiates high risk coronary disease families. J. Clin. Endocrin. Metab. 87, 1268-1273. (Pubitemid 36121098)
7. Deakin, S. P., James, R. W. (2004) Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. (Land.) 107, 435-447. (Pubitemid 39506735)
8. Draganov, D. I., Stetson, P. L., Watson, C. E., Billecke, S. S., La Du, B. N. (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem. 275, 33435-33442.
9. Ece, A., Gürkan, F., Celik, F., Bosnak, M., Yel, S., Balik, H., Erel, O. (2007) Paraoxonase, total antioxidant activity and peroxide levels in marasmic children: relationships with leptin. Clin. Biochem. 40, 634-639. (Pubitemid 46829073)
10. Fang, D. H., Fan, C. H., Ji, Q., Qi, B. X., Li, J, Wang, L. (2012) Different effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies. Mol. Biol. Rep. 39, 6801-6809.
11. Ferlay, J., Parkin, D. M., Steliarova-Foucher, E. (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer. 46, 745-781.
12. Flekač, M., Škrha, J., Zídková, K., Lacinová, Z., Hilgertová, J. (2008) Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol. Res. 57, 717-726.
13. th ed. Philadelphia-New York, Lippincott-Raven.
14. Goswami, B., Tayal, D., Gupta, N., Mallika, V. (2009) Paraoxonase: a multifaceted biomolecule. Clin. Chim. Acta 410, 1-12.
15. Hassan, M. M., Bondy, M. L., Wolff, R. A., Abbruzzese, J. L., Vauthey, J. N., Postere, P. W., Evans, D. B., Khan, R., Chou, T. H., Lenzi, R., Jiao, L., Li, D. (2007) Risk factors for pancreatic cancer: case-control study. Am. J. Gastroenterol. 102, 2696-2707. (Pubitemid 350179330)
16. Hendrick, C. C., Thorpe, S. R., Fu, M. X., Harper, C. M., Yoo, J., Kim, S. M., Wong, H., Peters, A. L. (2000) Glycation impairs high-density lipoprotein function. Diabetologia 43, 312-320. (Pubitemid 30163474)
17. Hussein, Y. M., Gharib, A. F., Etewa, R. L., ElSawy, W. H. (2011) Association of L55M a Q192 polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance. Mol. Cell. Biochem. 351, 117-123.
18. Institute of Health Information and Statistics of the Czech Republic (IHIS) and Council of the National Oncological Registry of the Czech Republic (NOR) (2011) Cancer Incidence 2008. ÚZIS and NOR ČR. Prague.
19. James, R. W. (2006) A long and winding road: defining the biological role and clinical importance of paraoxonase. Clin. Chem. Lab. Med. 44, 1052-1059.
20. Karaman, E., Uzun, H., Papila, I., Balci, H., Ozdilek, A., Genc, H., Yanardag, H., Papila, C. (2010) Serum paraoxonase activity and oxidative DNA damage in patients with laryngeal squamous cell carcinoma. J. Craniofac. Surg. 21, 1745-1749.
21. Kodydková, J., Vávrová, L., Zeman, M., Jirák, R., Macášek, J., Staňková, B., Tvrzická, E., Žák, A. (2009) Antioxidative enzymes and increased oxidative stress in depressive women. Clin. Biochem. 42, 1368-1374.
22. Krechler, T., Zeman, M., Vecka, M., Macášek, J., Jáchymová, M., Zima, T., Žák, A. (2011) Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma 58, 58-64.
23. Lee, C. H., Lee, K. Y., Choe, K. H., Hong, Y. C., Kim, Y. D., Kang, J. W., Kim, H. (2005) Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of paraoxonase-1 (PON-1) gene on lung cancer. J. Prev. Med. Publ. Health 38, 345-350.
24. Lenk, K., Schuler, G., Adams, V. (2010) Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Chachexia Sarcopenia Muscle 1, 9-21.
25. Leviev, I., James, R. W. (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20, 516-521. (Pubitemid 30086111)
26. Mackness, B., Mackness, M. I., Arron, S., Turkie, W., Durrington, P. N. (1997) Effect of molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 122, 265-268. (Pubitemid 27397197)
27. Maritim, A. C., Sanders, R. A., Watkins, J. B. (2003) Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17, 24-38. (Pubitemid 36410972)
28. McMillan, D. C. (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 12, 223-226.
29. Miller, S. A., Dykes, D. D., Polesky, H. F. (1988) A simple salting out extraction DNA from human nucleated cells. Nucleic Acids Res. 16, 1215.
30. Pannala, R., Leirness, J. B., Bamlet, W. R., Basu, A., Petersen, G. M., Chari, S. T. (2008) Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134, 981-987. (Pubitemid 351451984)
31. Précourt, L. P., Amre, D., Denis, M. C., Lavore, J. C., Delvin, E., Seidman, E., Levy, E. (2011) The three-gene paraoxonase family: physiologic roles, action and regulation. Atherosclerosis 214, 20-36.
32. Samra, Z. Q., Pervaiz, S., Shaheen, S., Dar, N., Athar, M. A. (2011) Determination of oxygen derived free radicals producer (xanthine oxidase) and scavenger (paraoxonase 1) enzymes and lipid parameters in different cancer patients. Clin. Lab. 57, 741-747.
33. Silvério, R., Lavino, A., Rossi Fanelli, F., Seelaender, M. (2011) L-carnitine and cancer cachexia: clinical and experimental aspects. J. Cachexia Sarcopenia Muscle 2, 37-44.
34. Soran, H., Younis, N. N., Charlton-Menys, V., Durrington, P. (2009) Variation in paraoxonase-1 activity and atherosclerosis. Curr. Opin. Lipidol. 20, 265-274.
35. Tavori, H., Aviram, M., Khatib, S., Musa, R., Mannheim, D., Karmeli, R., Vaya, J. (2011) Human carotid lesion linoleic acid hydroperoxide inhibits paraoxonase 1 (PON1) activity via reaction with PON1 free sulfhydryl cysteine 284. Free Radic. Biol. Med. 50, 148-156.
36. Valko, M., Rhodes, C. J., Moncol, J., Izakovic, M., Mazur, M. (2006) Free radicals, metals, and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 160, 1-40. (Pubitemid 43227479)
37. Van den Berg, S. W., Jansen, E. H., Kruijshoop, M., Beekhof, P. K., Blaak, E., van der Kallen, C. J., van Greevenbroek, M. M., Feskens, E. J. (2008) Paraoxonase 1 phenotype distribution and activity differ in subjects with newly diagnosed Type 2 diabetes (the CODAM Study). Diabet. Med. 25, 186-193. (Pubitemid 351293397)